The German ROP Registry
Standard
The German ROP Registry : data from 90 infants treated for retinopathy of prematurity. / Walz, Johanna M; Bemme, Sebastian; Pielen, Amelie; Aisenbrey, Sabine; Breuß, Helge; Alex, Anne F; Wagenfeld, Lars; Schiedel, Susanne; Krohne, Tim U; Stahl, Andreas; Retina.net ROP Registry.
In: ACTA OPHTHALMOL, Vol. 94, No. 8, 12.2016, p. e744-e752.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The German ROP Registry
T2 - data from 90 infants treated for retinopathy of prematurity
AU - Walz, Johanna M
AU - Bemme, Sebastian
AU - Pielen, Amelie
AU - Aisenbrey, Sabine
AU - Breuß, Helge
AU - Alex, Anne F
AU - Wagenfeld, Lars
AU - Schiedel, Susanne
AU - Krohne, Tim U
AU - Stahl, Andreas
AU - Retina.net ROP Registry
N1 - © 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
PY - 2016/12
Y1 - 2016/12
N2 - PURPOSE: The German retinopathy of prematurity (ROP) Registry collects data on treated ROP in a multicentre approach to analyse epidemiology and treatment patterns of severe ROP.METHODS: Nine centres entered data from 90 treated ROP infants (born between January 2011 and December 2013) into a central database. Analysis included incidence rate of severe ROP, demographic data, stage of ROP, treatment patterns, recurrence rates, relevant comorbidities and ophthalmological or systemic complications associated with treatment.RESULTS: Treatment rate for ROP was 3.2% of the screened population. The most frequent ROP stage at time of treatment was zone II, stage 3 + (137 eyes). Treatment was bilateral in 97% of infants. Treatment patterns changed over time from 7% anti-vascular endothelial growth factor (VEGF) monotherapy in 2011 to 32% in 2014. Overall, laser treatment was the predominant treatment. However, all infants with zone I disease received anti-VEGF treatment. About 19% of infants required retreatment (16% of laser-treated and 21% of anti-VEGF treated infants). Mean time between first and second treatment was 3.8 weeks (± 11 days) for laser-treated and 10.4 weeks (± 60 days) for anti-VEGF-treated infants.CONCLUSION: This study is the first multicentre analysis of severe ROP in Germany. The identified treatment patterns find laser as the most prevalent form of therapy, with an increasing use of anti-VEGF therapy over recent years. Recurrence rates were relatively high overall with slightly higher recurrence rates and later recurrence times in the anti-VEGF group. Anti-VEGF was predominantly used for high-risk stages like AP-ROP and zone I disease.
AB - PURPOSE: The German retinopathy of prematurity (ROP) Registry collects data on treated ROP in a multicentre approach to analyse epidemiology and treatment patterns of severe ROP.METHODS: Nine centres entered data from 90 treated ROP infants (born between January 2011 and December 2013) into a central database. Analysis included incidence rate of severe ROP, demographic data, stage of ROP, treatment patterns, recurrence rates, relevant comorbidities and ophthalmological or systemic complications associated with treatment.RESULTS: Treatment rate for ROP was 3.2% of the screened population. The most frequent ROP stage at time of treatment was zone II, stage 3 + (137 eyes). Treatment was bilateral in 97% of infants. Treatment patterns changed over time from 7% anti-vascular endothelial growth factor (VEGF) monotherapy in 2011 to 32% in 2014. Overall, laser treatment was the predominant treatment. However, all infants with zone I disease received anti-VEGF treatment. About 19% of infants required retreatment (16% of laser-treated and 21% of anti-VEGF treated infants). Mean time between first and second treatment was 3.8 weeks (± 11 days) for laser-treated and 10.4 weeks (± 60 days) for anti-VEGF-treated infants.CONCLUSION: This study is the first multicentre analysis of severe ROP in Germany. The identified treatment patterns find laser as the most prevalent form of therapy, with an increasing use of anti-VEGF therapy over recent years. Recurrence rates were relatively high overall with slightly higher recurrence rates and later recurrence times in the anti-VEGF group. Anti-VEGF was predominantly used for high-risk stages like AP-ROP and zone I disease.
KW - Angiogenesis Inhibitors
KW - Birth Weight
KW - Comorbidity
KW - Female
KW - Germany
KW - Gestational Age
KW - Humans
KW - Incidence
KW - Infant
KW - Infant, Newborn
KW - Intravitreal Injections
KW - Laser Coagulation
KW - Male
KW - Recurrence
KW - Registries
KW - Retinopathy of Prematurity
KW - Vascular Endothelial Growth Factor A
KW - Journal Article
KW - Multicenter Study
U2 - 10.1111/aos.13069
DO - 10.1111/aos.13069
M3 - SCORING: Journal article
C2 - 27197876
VL - 94
SP - e744-e752
JO - ACTA OPHTHALMOL
JF - ACTA OPHTHALMOL
SN - 1755-375X
IS - 8
ER -